Association of High Expression of Groβ with Clinical and Pathological Characteristics of Unfavorable Prognosis in Gastrointestinal Stromal Tumors

Abstract EN

GROβ (CXCL2) is a chemokine produced by endotoxin-treated macrophages that mediates inflammation and tumor development.

However, little is known about GROβ expression in gastrointestinal stromal tumors (GIST) or the relationship between GROβ expression and clinical attributes of GIST.

GROβ expression was examined via immunohistochemical staining of 173 GIST samples using tissue microarray.

The relationship between GROβ expression and relevant patient and tumor characteristics was assessed, using chi-square tests.

Univariate and multivariate analysis was carried out using the Cox regression method.

High GROβ cytoplasm staining was detected in 56 (32.4%) specimens; high GROβ nuclear staining was detected in 64 (37.0%) specimens.

High GROβ cytoplasm staining was significantly associated with patients’ age (P=0.043) and tumor location (P=0.014), while high GROβ nucleus staining was significantly associated with mitotic index (P=0.034), tumor location (P=0.049), and AFIP-Miettinen risk classification (P=0.048).

Kaplan-Meier survival curves showed GIST patients with low GROβ cytoplasm expression (P=0.023) and mitotic index < 6 per 50 HPFs (P=0.026) to have a more favorable prognosis.

These findings indicate that GROβ expression correlates with malignant GIST phenotypes and could be an unfavorable prognostic marker in patients with GIST.